About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID
Tg(tetO-Ifng)184Pop
transgene insertion 184, Brian Popko
MGI:4355871
Summary 7 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
cx1
Tg(GFAP-tTA)67Pop/0
Tg(tetO-Ifng)184Pop/0
B6.Cg-Tg(GFAP-tTA)67Pop Tg(tetO-Ifng)184Pop MGI:4355901
cx2
Tg(GFAP-tTA)78Pop/0
Tg(tetO-Ifng)184Pop/0
B6.Cg-Tg(GFAP-tTA)78Pop Tg(tetO-Ifng)184Pop MGI:4355976
cx3
Tg(GFAP-tTA)67Pop/0
Tg(tetO-Ifng)184Pop/0
involves: 129S/SvEv * C57BL/6 * DBA/2 MGI:4355902
cx4
Stat1tm1Rds/Stat1tm1Rds
Tg(GFAP-tTA)67Pop/0
Tg(tetO-Ifng)184Pop/0
involves: 129S/SvEv * C57BL/6 * DBA/2 MGI:4355903
cx5
Eif2ak3tm1Dron/Eif2ak3tm1Dron
Tg(GFAP-tTA)110Pop/0
Tg(tetO-Ifng)184Pop/0
involves: 129S6/SvEvTac * C57BL/6 * DBA/2 * Swiss Webster MGI:4355948
cx6
Eif2ak3tm1Dron/Eif2ak3+
Tg(GFAP-tTA)110Pop/0
Tg(tetO-Ifng)184Pop/0
involves: 129S6/SvEvTac * C57BL/6 * DBA/2 * Swiss Webster MGI:4355950
cx7
Tg(GFAP-tTA)110Pop/0
Tg(tetO-Ifng)184Pop/0
involves: 129S6/SvEvTac * C57BL/6 * DBA/2 * Swiss Webster MGI:4355952


Genotype
MGI:4355901
cx1
Allelic
Composition
Tg(GFAP-tTA)67Pop/0
Tg(tetO-Ifng)184Pop/0
Genetic
Background
B6.Cg-Tg(GFAP-tTA)67Pop Tg(tetO-Ifng)184Pop
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(GFAP-tTA)67Pop mutation (0 available)
Tg(tetO-Ifng)184Pop mutation (1 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
N
• if double transgenic pups receive doxycycline through gestation and postnatally, or through gestation but treatment stops at birth, animals appear healthy with no histologic lesions
• if pregnant mice do not receive doxycycline (dox) during gestation, >80% of pups die in the neonatal period; double transgenic animals are never recovered
• all ataxic mice (when dox treatment is stopped at E16) die at 3-4 weeks from a progressive neurological syndrome

growth/size/body
• if double transgenic pups receive doxycycline until E16, about 80% start to show growth retardation in the second postnatal week

tumorigenesis
• necropsy of animals dying at 3-4 weeks shows infiltrative lesions of cerebellar hemispheres composed of tumor cells (mitotically active, primitive-appearing cells with hyperchromatic nuclei and little cytoplasm)
• when affected mice start to receive dox again at P16, tumors show less necrosis and apoptosis than untreated mutants
• pups which received doxycline to birth with cessation at P0 have normal cerebellar architecture and do not show tumor formation or migration abnormalities of granule cell precursors

behavior/neurological
• if double transgenic pups receive doxycycline until E16, about 80% develop tremor around P12
• if double transgenic pups receive doxycycline until E16, about 80% develop ataxia around P12

nervous system
• tumor cells are observed primarily in the molecular layer and external granule layer, but also frequently invading the deep cerebellar white matter and brainstem structures
• at P12, mice which received doxycycline until E16 display lesions confined to the EGL which shows a diffuse hyperplasia throughout the cerebellar hemispheres
• at P16, affected animals show marked proliferation of the EGL with diffuse infiltration of the molecular layer, consistent with malignant tumor formation; in contrast, control animals exhibit complete regression of the EGL
• necropsy of animals dying at 3-4 weeks shows infiltrative lesions of cerebellar hemispheres composed of tumor cells (mitotically active, primitive-appearing cells with hyperchromatic nuclei and little cytoplasm)
• when affected mice start to receive dox again at P16, tumors show less necrosis and apoptosis than untreated mutants
• pups which received doxycline to birth with cessation at P0 have normal cerebellar architecture and do not show tumor formation or migration abnormalities of granule cell precursors

Mouse Models of Human Disease
OMIM ID Ref(s)
Medulloblastoma; MDB 155255 J:94092




Genotype
MGI:4355976
cx2
Allelic
Composition
Tg(GFAP-tTA)78Pop/0
Tg(tetO-Ifng)184Pop/0
Genetic
Background
B6.Cg-Tg(GFAP-tTA)78Pop Tg(tetO-Ifng)184Pop
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(GFAP-tTA)78Pop mutation (0 available)
Tg(tetO-Ifng)184Pop mutation (1 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
growth/size/body
• when dams are treated with doxycycline (dox) until E16, double transgenic offspring are runted postnatally and display a failure to thrive

nervous system
• modest numbers of T lymphocytes are observed scattered throughout the cerebellum of double transgenic animals that received dox treatment until E16; this is not observed in controls
• at P14, external granule layer (EGL) persists in mutants that receive dox until E16 whereas in controls the EGL is no longer present
• at P14, numerous proliferating cells are detected, as well as increased vasculature, when animals received dox until E16
• double transgenic pups which received dox during development until E16 show significant enlargement of the cerebellum at P14
• gliosis and astrocyte hypertrophy is also observed

behavior/neurological

immune system
• at P14, IFN-g protein was detectable only in lysates of cerebellum from double transgenic mice that had been released from doxycycline at E16, but not in control samples
• modest numbers of T lymphocytes are observed scattered throughout the cerebellum of double transgenic animals that received dox treatment until E16; this is not observed in controls




Genotype
MGI:4355902
cx3
Allelic
Composition
Tg(GFAP-tTA)67Pop/0
Tg(tetO-Ifng)184Pop/0
Genetic
Background
involves: 129S/SvEv * C57BL/6 * DBA/2
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(GFAP-tTA)67Pop mutation (0 available)
Tg(tetO-Ifng)184Pop mutation (1 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
nervous system
• when doxycycline treatment is stopped at E 16, around 90% of double mutants develop medulloblastoma and die by P21

tumorigenesis
• when doxycycline treatment is stopped at E 16, around 90% of double mutants develop medulloblastoma and die by P21

Mouse Models of Human Disease
OMIM ID Ref(s)
Medulloblastoma; MDB 155255 J:94092




Genotype
MGI:4355903
cx4
Allelic
Composition
Stat1tm1Rds/Stat1tm1Rds
Tg(GFAP-tTA)67Pop/0
Tg(tetO-Ifng)184Pop/0
Genetic
Background
involves: 129S/SvEv * C57BL/6 * DBA/2
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Stat1tm1Rds mutation (2 available); any Stat1 mutation (24 available)
Tg(GFAP-tTA)67Pop mutation (0 available)
Tg(tetO-Ifng)184Pop mutation (1 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
N
• if doxycycline treatment is stopped at E16, pups display a milder phenotype and survive at least until 8 weeks of age
• no double transgenic pups are recovered if dams did not receive any doxycycline treatment

behavior/neurological
• if doxycycline treatment is stopped at E16, pups display minor ataxia at 2 weeks
• if doxycycline treatment is stopped at E16, pups display minor ataxia at 2 weeks

tumorigenesis
N
• if doxycycline treatment is stopped at E16, no tumors are observed in cerebella of adult mice




Genotype
MGI:4355948
cx5
Allelic
Composition
Eif2ak3tm1Dron/Eif2ak3tm1Dron
Tg(GFAP-tTA)110Pop/0
Tg(tetO-Ifng)184Pop/0
Genetic
Background
involves: 129S6/SvEvTac * C57BL/6 * DBA/2 * Swiss Webster
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Eif2ak3tm1Dron mutation (1 available); any Eif2ak3 mutation (20 available)
Tg(GFAP-tTA)110Pop mutation (1 available)
Tg(tetO-Ifng)184Pop mutation (1 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• pups die around P12 regardless whether dams received doxycycline to the end of gestation or until E14




Genotype
MGI:4355950
cx6
Allelic
Composition
Eif2ak3tm1Dron/Eif2ak3+
Tg(GFAP-tTA)110Pop/0
Tg(tetO-Ifng)184Pop/0
Genetic
Background
involves: 129S6/SvEvTac * C57BL/6 * DBA/2 * Swiss Webster
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Eif2ak3tm1Dron mutation (1 available); any Eif2ak3 mutation (20 available)
Tg(GFAP-tTA)110Pop mutation (1 available)
Tg(tetO-Ifng)184Pop mutation (1 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• greater than 90% of animals die by postnatal day 27

growth/size/body
• pups are significantly smaller than controls littermates when doxycycline treatment is stopped on E14

nervous system
• >60% of animals display tonic seizures
• in cervical spinal cord at P14, number of apoptotic oligodendrocytes is significantly greater than in controls when doxycycline treatment is stopped at E14
• when doxycycline treatment is stopped at E14, very few oligodendrocytes are detected in corpus callosum and cerebellum at P14
• if mice are treated with doxycycline until they reach maturity (4 weeks) and then are released from doxycycline, oligodendrocyte survival is unaffected
• >80% of axons are unmyelinated compared to 30% of spinal cord axons in double mutants on a wild-type Eif2ak3 background when doxycycline treatment is stopped at E14; in mice continuously receiving doxycycline treatment, <10% of spinal cord axons are unmyelinated
• if mice are treated with doxycycline until they reach maturity (4 weeks) and then are released from doxycycline, normal myelin is observed in the central nervous system
• level of myelin in CNS is significantly reduced at P14 compared to double transgenic mice with wild-type Eif2ak3
• in cervical spinal cord at P14, number of apoptotic oligodendrocytes is significantly greater than in controls when doxycycline treatment is stopped at E14

behavior/neurological
• severe tremors are observed
• >60% of animals display tonic seizures

cellular
• in cervical spinal cord at P14, number of apoptotic oligodendrocytes is significantly greater than in controls when doxycycline treatment is stopped at E14




Genotype
MGI:4355952
cx7
Allelic
Composition
Tg(GFAP-tTA)110Pop/0
Tg(tetO-Ifng)184Pop/0
Genetic
Background
involves: 129S6/SvEvTac * C57BL/6 * DBA/2 * Swiss Webster
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(GFAP-tTA)110Pop mutation (1 available)
Tg(tetO-Ifng)184Pop mutation (1 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
N
• when doxycycline treatment is stopped at E14, double transgenic offspring exhibit good survival

behavior/neurological
• pups exhibit minor tremor
• pups exhibit minor ataxia





Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Tumor Biology (MTB), Gene Ontology (GO), MouseCyc
Citing These Resources
Funding Information
Warranty Disclaimer & Copyright Notice
Send questions and comments to User Support.
last database update
04/26/2016
MGI 6.03
The Jackson Laboratory